{
    "id": "wrong_mix_random_foundationPlace_00001_0",
    "rank": 71,
    "data": {
        "url": "https://www.denalitherapeutics.com/leadership",
        "read_more_link": "",
        "language": "en",
        "title": "Leadership",
        "top_image": "https://www.denalitherapeutics.com/sites/default/files/2021-03/Denali_Logo_On_Gray_02.png",
        "meta_img": "https://www.denalitherapeutics.com/sites/default/files/2021-03/Denali_Logo_On_Gray_02.png",
        "images": [
            "https://www.denalitherapeutics.com/sites/default/files/2021-04/Denali_Logo_02.png",
            "https://www.denalitherapeutics.com/sites/default/files/2020-11/utsav-shah-368557-unsplash_Edit.jpg",
            "https://www.denalitherapeutics.com/sites/default/files/2021-07/Ryan%20Watts%20Headshot.jpg",
            "https://www.denalitherapeutics.com/sites/default/files/2021-07/Ryan%20Watts%20Headshot.jpg",
            "https://www.denalitherapeutics.com/sites/default/files/2020-11/alex-schuth_0.jpg",
            "https://www.denalitherapeutics.com/sites/default/files/2020-11/alex-schuth_0.jpg",
            "https://www.denalitherapeutics.com/sites/default/files/2020-11/carole-ho.jpg",
            "https://www.denalitherapeutics.com/sites/default/files/2020-11/carole-ho.jpg",
            "https://www.denalitherapeutics.com/sites/default/files/2020-11/dana-anderson-headshot-2.jpg",
            "https://www.denalitherapeutics.com/sites/default/files/2020-11/dana-anderson-headshot-2.jpg",
            "https://www.denalitherapeutics.com/sites/default/files/2020-11/cindy-dunkle.jpg",
            "https://www.denalitherapeutics.com/sites/default/files/2020-11/cindy-dunkle.jpg",
            "https://www.denalitherapeutics.com/sites/default/files/2020-11/joe-lewcock-2.jpg",
            "https://www.denalitherapeutics.com/sites/default/files/2020-11/joe-lewcock-2.jpg",
            "https://www.denalitherapeutics.com/sites/default/files/2020-11/chris-walsh.jpg",
            "https://www.denalitherapeutics.com/sites/default/files/2020-11/chris-walsh.jpg",
            "https://www.denalitherapeutics.com/sites/default/files/2021-09/katieprofile.png",
            "https://www.denalitherapeutics.com/sites/default/files/2021-09/katieprofile.png",
            "https://www.denalitherapeutics.com/sites/default/files/2020-11/peter-chin.jpg",
            "https://www.denalitherapeutics.com/sites/default/files/2020-11/peter-chin.jpg",
            "https://www.denalitherapeutics.com/sites/default/files/2022-05/Kirk%20Henne.jpg",
            "https://www.denalitherapeutics.com/sites/default/files/2022-05/Kirk%20Henne.jpg",
            "https://www.denalitherapeutics.com/sites/default/files/2020-11/erica-kratz.jpg",
            "https://www.denalitherapeutics.com/sites/default/files/2020-11/erica-kratz.jpg",
            "https://www.denalitherapeutics.com/sites/default/files/2020-11/tyler-nielsen.jpg",
            "https://www.denalitherapeutics.com/sites/default/files/2020-11/tyler-nielsen.jpg",
            "https://www.denalitherapeutics.com/sites/default/files/2023-03/MP%20Headshot%20Edit.jpg",
            "https://www.denalitherapeutics.com/sites/default/files/2023-03/MP%20Headshot%20Edit.jpg",
            "https://www.denalitherapeutics.com/sites/default/files/2020-11/matt-troyer.jpg",
            "https://www.denalitherapeutics.com/sites/default/files/2020-11/matt-troyer.jpg",
            "https://www.denalitherapeutics.com/sites/default/files/2023-05/Cynthia%20Wong-2.jpg",
            "https://www.denalitherapeutics.com/sites/default/files/2023-05/Cynthia%20Wong-2.jpg",
            "https://www.denalitherapeutics.com/sites/default/files/2023-05/image000000.jpeg",
            "https://www.denalitherapeutics.com/sites/default/files/2023-05/image000000.jpeg",
            "https://www.denalitherapeutics.com/sites/default/files/2022-05/Wei%20Dong.jpg",
            "https://www.denalitherapeutics.com/sites/default/files/2022-05/Wei%20Dong.jpg",
            "https://www.denalitherapeutics.com/sites/default/files/2021-07/20210622-DSC_8155-min.jpg",
            "https://www.denalitherapeutics.com/sites/default/files/2021-07/20210622-DSC_8155-min.jpg",
            "https://www.denalitherapeutics.com/sites/default/files/2021-02/IMG-0072.jpg",
            "https://www.denalitherapeutics.com/sites/default/files/2021-02/IMG-0072.jpg",
            "https://www.denalitherapeutics.com/sites/default/files/2023-05/Mark%20Kafka.jpg",
            "https://www.denalitherapeutics.com/sites/default/files/2023-05/Mark%20Kafka.jpg",
            "https://www.denalitherapeutics.com/sites/default/files/2024-03/Chris%20Koth.jpg",
            "https://www.denalitherapeutics.com/sites/default/files/2024-03/Chris%20Koth.jpg",
            "https://www.denalitherapeutics.com/sites/default/files/2021-10/Fabian%20%281%29.jpg",
            "https://www.denalitherapeutics.com/sites/default/files/2021-10/Fabian%20%281%29.jpg",
            "https://www.denalitherapeutics.com/sites/default/files/2022-07/Michael%20Ostland-2.jpg",
            "https://www.denalitherapeutics.com/sites/default/files/2022-07/Michael%20Ostland-2.jpg",
            "https://www.denalitherapeutics.com/sites/default/files/2023-05/Mark%20Rowen%202022%20-%20final.jpg",
            "https://www.denalitherapeutics.com/sites/default/files/2023-05/Mark%20Rowen%202022%20-%20final.jpg",
            "https://www.denalitherapeutics.com/sites/default/files/2020-11/jennifer-cook.jpg",
            "https://www.denalitherapeutics.com/sites/default/files/2020-11/jennifer-cook.jpg",
            "https://www.denalitherapeutics.com/sites/default/files/2020-11/jay-flatley.jpg",
            "https://www.denalitherapeutics.com/sites/default/files/2020-11/jay-flatley.jpg",
            "https://www.denalitherapeutics.com/sites/default/files/2022-02/ErikHarris_Ultragenyx_2021_009.jpg",
            "https://www.denalitherapeutics.com/sites/default/files/2022-02/ErikHarris_Ultragenyx_2021_009.jpg",
            "https://www.denalitherapeutics.com/sites/default/files/2020-11/peter-klein.jpg",
            "https://www.denalitherapeutics.com/sites/default/files/2020-11/peter-klein.jpg",
            "https://www.denalitherapeutics.com/sites/default/files/2020-11/steve-krognes.jpg",
            "https://www.denalitherapeutics.com/sites/default/files/2020-11/steve-krognes.jpg",
            "https://www.denalitherapeutics.com/sites/default/files/2020-11/vicki-sato.jpg",
            "https://www.denalitherapeutics.com/sites/default/files/2020-11/vicki-sato.jpg",
            "https://www.denalitherapeutics.com/sites/default/files/2020-11/david-schenkein.jpg",
            "https://www.denalitherapeutics.com/sites/default/files/2020-11/david-schenkein.jpg",
            "https://www.denalitherapeutics.com/sites/default/files/2020-11/marc-tessier-lavigne.jpg",
            "https://www.denalitherapeutics.com/sites/default/files/2020-11/marc-tessier-lavigne.jpg",
            "https://www.denalitherapeutics.com/sites/default/files/2021-01/nancythornberryBW.png",
            "https://www.denalitherapeutics.com/sites/default/files/2021-01/nancythornberryBW.png",
            "https://www.denalitherapeutics.com/sites/default/files/2021-07/Ryan%20Watts%20Headshot.jpg",
            "https://www.denalitherapeutics.com/sites/default/files/2021-07/Ryan%20Watts%20Headshot.jpg"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": null,
        "summary": "",
        "meta_description": "Denali Therapeutics is dedicated to defeating neurodegenerative diseases through rigorous therapeutic discovery and development.",
        "meta_lang": "en",
        "meta_favicon": "/themes/custom/site-theme/favicon.ico",
        "meta_site_name": "Denali",
        "canonical_link": "https://www.denalitherapeutics.com/leadership",
        "text": "Carole Ho is our Chief Medical Officer and Head of Development. At Denali, Carole has built an integrated Development organization that is responsible for advancing therapeutic candidates from pre-IND enabling studies through Phase 1 to Phase 3 clinical trials. Under Caroleâs leadership, her team has delivered on Denaliâs biomarker driven development strategy to enable early target and pathway engagement in the clinic for therapeutics in development for Parkinsonâs disease, Alzheimer's disease, and ALS.\n\nCarole previously served as Vice President of Genentech Early Clinical Development and was responsible for delivery of pivotal trial-ready drug candidates in Neurology, Ophthalmology, Immunology, and Infectious Disease. During her 8-year tenure at Genentech, Carole held roles with leadership responsibility across multiple early- and late-stage clinical programs including RituxanÂ® for Wegenerâs granulomatosis and microscopic polyangiitis, ocrelizumab for Multiple Sclerosis, lampalizumab for dry AMD, and crenezumab for Alzheimerâs Disease. At Genentech, in collaboration with Banner Health, Carole's team led the initiation of the world's first prevention trial in Alzheimer's disease in participants at risk for dementia due to a genetic mutation.\n\nCarole completed her residency in Neurology at Harvard Medical School at the Massachusetts General Hospital / Brigham and Womenâs Hospital, where she also served as Chief Resident. She obtained her M.D. from Cornell University and S.B. in Biochemical Sciences from Harvard College. Prior to her Industry career, Carole was on Faculty in the Department of Neurology at Stanford University. Carole currently serves on the Board of Directors of Beam Therapeutics.\n\nDana Andersen is our Chief Technical and Manufacturing Officer and is responsible for overseeing the development of manufacturing processes, production, quality control & assurance and clinical supply to support the Denali therapeutic portfolio.\n\nPreviously, he worked at Genentech for nearly 23 years, most recently as Vice President and Global Head of Technical Development Project & Portfolio Management for the Roche large and small molecule development portfolio. Earlier he held several leadership roles spanning biologics manufacturing process development eventually becoming Vice President of Pharmaceutical Development.\n\nDana is a fellow of the American Institute for Medical and Biological Engineering and received a B.S. from the University of Colorado at Boulder, and a M.S. and Ph.D. from Stanford University, all in chemical engineering with a focus on biological systems.\n\nCindy Dunkle serves as Chief People Officer at Denali. In this position, she oversees all aspects of human resources, facilities, and environmental health and safety.\n\nCindy has been instrumental in the successful growth of the company, positioning science and leadership as a focus in attracting top talent. She drives HR strategy and value creation, fosters a culture of learning and innovation to enable each individual achieve their unique potential. Cindy has 25 years of experience with an emphasis in compensation, organizational development and talent acquisition.\n\nPrior to Denali, Cindy held roles of increasing responsibility across corporate staffing and development functions at Avalanche Biotechnologies and Genentech. Cindy obtained a B.S. from Metropolitan State University.\n\nPeter leads the Late Clinical function at Denali. In this role, he coordinates late stage clinical science and medical affairs activities as the portfolio advances through the lifecycle. His group facilitates the design and oversight of late stage clinical trials to support regulatory approval, augments the medical communityâs understanding of neurological disease mechanisms, and characterizes the evidence base to support appropriate use of new therapeutics upon approval.\n\nPeter most recently served as Group Medical Director for Neuroscience in U.S. Medical Affairs at Genentech and previously held leadership roles in neuroscience development at Genentech/Roche and Novartis, contributing to the global development and clinical application of therapies approved for relapsing and progressive forms of multiple sclerosis, including fingolimod, siponimod and ocrelizumab. For over a decade he has also engaged in advancing clinical research platforms through initiatives sponsored by NIH-NINDS, C-PATH, patient advocacy groups, and various academic-industry consortia.\n\nPeter completed his B.A. in Molecular and Cell Biology at the University of California at Berkeley, M.D. at Dartmouth, neurology residency at the University of Washington, and fellowship as a Robert Wood Johnson Foundation Clinical Scholar at UCLA, where he also obtained an M.S. in Health Services through the School of Public Health.\n\nMatt Troyer leads the Early Clinical function and is responsible for overseeing a team of physician-scientists who execute Denaliâs early clinical programs. The Early Clinical group partners with pre-clinical teams, including Translational and Development Sciences, to design and conduct first-in-human, biomarker, experimental medicine and other early studies in healthy subjects and patients. Matt and the Early Clinical team execute the first clinical investigations that drive Denaliâs biomarker-driven development strategy.\n\nMatt is a neurologist with subspecialty training in Parkinsonâs disease and Movement Disorders and 14 years of early clinical leadership. Matt previously led early development programs at Medivation and at Merck & Co., Inc. where he was Executive Director and Neuroscience Therapeutic Area lead for Early Clinical Development, with responsibility for pre-clinical to proof-of-concept programs in Alzheimerâs disease, Parkinsonâs disease, sleep disorders, pain, migraine, schizophrenia and other CNS indications.\n\nMatt completed neurology residency training at Harvard Medical School in the Longwood Area Program and completed a fellowship in Parkinsonâs disease and Movement disorders at the Institute of Neurology, Queen Square, London. Following his clinical fellowship, Matt did a postdoctoral research fellowship in the laboratory of Robert Edwards at UCSF, focusing on basic mechanisms of presynaptic function and Parkinsonâs disease. Matt subsequently joined the Neurology faculty at UCSF with both clinical and research responsibilities. Matt received his M.D. from Stanford University and a B.A. in biology from Illinois Wesleyan University.\n\nCynthia leads Portfolio Planning and Program Management at Denali and is responsible for Denaliâs growing portfolio of 10+ programs in various stages of research and clinical development. Cynthia is the Program Director of Denaliâs LRRK2 program. In addition, she is involved in developing and evolving Denaliâs project team system and decision making processes to support a project-centric organization, whereby project teams are enabled to make high quality decisions with speed.\n\nPrior to Denali, Cynthia was an Associate Director at Genentechâs Research and Early Development Portfolio Planning and Operations group, culminating a career of 12 years at Genentech. Cynthia managed programs from pre-IND through approval in the inflammation, ophthalmology, infectious disease, and oncology disease areas, including products on the market such as Ocrevus (ocrelizumab), Tecentriz (atezolizumab), and Lucentis (ranibizumab).\n\nCynthia has a B.A. from the University of California at Berkeley in Mass Communications and East Asian Studies.\n\nLaura leads Investor Relations at Denali, bringing more than two decades of experience in corporate and scientific communications for biotech companies.\n\nPrior to Denali, she was Vice President of Corporate Affairs at BlackThorn Therapeutics, a privately held company focused on developing precision medicines for neuropsychiatric disorders. Before joining BlackThorn, she was Vice President of Investor Relations at Aimmune Therapeutics, Inc., a leading food allergy therapeutics company. Prior to that, she held positions in corporate communications at Threshold Pharmaceuticals, Inc., and FibroGen, Inc. At both companies, she was also responsible for scientific communications related to novel therapeutic platforms in oncology, fibrosis, and anemia.\n\nLaura has a Ph.D. in Biological Sciences and a B.S. in Zoology from The University of Texas at Austin.\n\nJennifer Cook was previously the Chief Executive Officer of GRAIL. Jennifer also spent time at Roche Pharmaceuticals/Genentech where she held a number of senior management positions, covering the full lifecycle of product development and commercialization. From 2013 to 2016 she was Head of Region Europe for Roche Pharmaceuticals, where she was responsible for the commercial success of Europe and leading more than 5,500 employees across the 28 countries of the region. Other key positions during her 25-year tenure at Roche/Genentech included leading Global Clinical Operations, US and Global Product Portfolio Management, a US Commercial Business Unit, and Market Development.\n\nJennifer started her career in research and early development at Genentech and a venture-backed startup company. In 2016, Jennifer was recognized for her contributions to the healthcare industry and inspirational leadership when she was named Woman of the Year by the Healthcare Businesswomenâs Association. Jennifer holds a BA in human biology and an MS in biology from Stanford University, as well as an MBA from the Haas School of Business at University of California, Berkeley.\n\nJay led Illumina as CEO from 1999 until 2016, served as Executive Chairman from July 2016 to December 2019, and now serves as Chairman of the Board of Directors. During his tenure as CEO, he took the company from $1.3 million in sales in 2000 to $2.2 billion in 2015, representing a compound annual growth rate of 64 percent. He oversaw the companyâs expansion from microarrays into next-generation sequencing with the acquisition of Solexa in 2006, and from research into clinical and applied markets. Under his leadership, Illumina was named multiple times to the Deloitte & Touche Fast 50 and Fast 500 lists, as well as to the Forbes 25 Fastest-Growing Tech Companies (2007, 2009 and 2010), the Fortune 100 Fastest-Growing Companies (2010 and 2011) lists, and recognition by MIT Technology Review as the Worldâs Smartest Company in 2014.\n\nIn addition to his work at Illumina, he serves on the Boards of Directors at Coherent, Denali, Iridia, on the Board of Trustees for The Salk Institute, and is an Advisory Board member for UC San Diegoâs Moores Cancer Center.\n\nPreviously, Jay served on the Board of Juno Therapeutics until their acquisition by Celgene in 2018, and served as President and Chief Executive Officer of Molecular Dynamics, later acquired by Amersham Pharmacia Biotech and now a part of GE Healthcare. As a co-founder and member of the board of directors for Molecular Dynamics he led the company to its initial public offering in 1993. While there, he also helped Molecular Dynamics develop and launch over 15 major instrumentation systems, including the first capillary-based DNA sequencer. Prior to joining Molecular Dynamics, Jay was Vice President of Engineering and Strategic Planning for Plexus Computers, Executive Vice President for Manning Technologies and held various positions at Spectra Physics.\n\nJay received a B.A. in economics from Claremont McKenna College and a B.S. and M.S. (summa cum laude) in industrial engineering from Stanford University.\n\nPeter Klein joined the Board of Directors as an independent director. Mr. Klein has 25 years of experience as a senior finance executive. He served as Chief Financial Officer of Microsoft Corporation from November 2009 until May 2013 and spent over 11 years at Microsoft. Most recently, he served as Chief Financial Officer of WME, a global leader in sports and entertainment marketing, from January 2014 until June 2014.\n\nPeter holds a B.A. from Yale University and an M.B.A from University of Washington. He also serves on the board of directors of Apptio Inc. and F5 Networks, Inc., both publicly traded companies.\n\nSteve Krognes is a member of the Board of Directors and Denali's former Chief Financial Officer.\n\nSteve previously worked at Genentech and Roche for twelve years. At Genentech, he served as CFO and as a member of the Executive Committee for six years, where he was responsible for finance, site services and IT. Steve also represented Genentech on the Board and Executive Committee of the California Life Science Association and served as Chairman of the Genentech Access to Care Foundation.\n\nAt Roche in Switzerland, Steve led the global Mergers & Acquisition team for more than five years. Under Steveâs leadership, the M&A team executed more than 30 transactions worldwide, including the acquisitions of Ventana Medical Systems and Genentech. Steve worked as an investment banker at Goldman Sachs in London, a management consultant at McKinsey in London, and as a venture capitalist in Stockholm.\n\nSteve holds an M.B.A. from Harvard Business School, a B.S. in economics from the Wharton School of the University of Pennsylvania and is a Second Lieutenant in the Royal Norwegian Air Force.\n\nDr. Schenkein joined Agios in August 2009 as the Chief Executive Officer and a member of our board of directors and has been a hematologist and medical oncologist for more than 20 years. He currently serves as an adjunct attending physician in hematology at Tufts Medical Center. Prior to joining Agios, from March 2006 to July 2009, Dr. Schenkein was the Senior Vice President, clinical hematology/oncology, at Genentech, Inc., a pharmaceutical company, where he was responsible for numerous successful oncology drug approvals and leading the medical and scientific strategies for their BioOncology portfolio.\n\nWhile at Genentech, he served as an adjunct clinical professor of medical oncology at Stanford University School of Medicine. Prior to joining Genentech, he served as the Senior Vice President of clinical research at Millennium Pharmaceuticals, Inc. (a wholly-owned subsidiary of Takeda Pharmaceuticals Company Limited), overseeing the clinical development and worldwide approval of VelcadeÂ®, a first-in-class cancer therapy now approved to treat multiple myeloma and Non-Hodgkin's lymphoma. He currently serves on the board of directors of Foundation Medicine, Inc., bluebird bio, Inc., and Denali Therapeutics Inc.\n\nDr. Schenkein holds a B.A. in chemistry from Wesleyan University and an M.D. from the State University of New York Upstate Medical School."
    }
}